Alzinova AB (publ) (OM: ALZ)
Health Care · Biotechnology · SE
Skr0.85
+3.79% today · -48.5% 1Y
Alzinova AB (publ) (OM: ALZ) operates in the Biotechnology industry within the Health Care sector. The company is valued at $17.53M and employs 7 people.
Over the last twelve months the share price has lost 48.5%, trading between 0.38 and 2.28.
Tweenvest scores Alzinova AB (publ) across four factors: quality 45/100, value 51/100, growth 81/100. Its strongest factor is growth.
ALZ price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $17.53M
- Revenue (TTM)
- $230.19K
- P/E
- —
- EPS
- —
- Dividend yield
- —
- Beta (5Y)
- 1.11
- 52-week high
- Skr2.28
- 52-week low
- Skr0.38
- Avg volume (3M)
- —
- Shares outstanding
- 202.64M
- Employees
- 7
- Next earnings
- —
About Alzinova AB (publ)
Alzinova AB (publ) is a Swedish biotechnology company dedicated to advancing novel immunotherapies against Alzheimer's disease. Their primary investigational product, ALZ-101, is a vaccine specifically designed to target oligomers responsible for Alzheimer's. Additionally, they are developing ALZ-201, a monoclonal antibody aimed at neutralizing harmful amyloid-beta (Aß) oligomers. Established in 2011, the company's operations are headquartered in Mölndal, Sweden.
- ISIN
- SE0007413455
- Founded
- 2011
- Listed since
- Nov 25, 2015
- Exchange
- OMX Nordic Exchange Stockholm
- Currency
- SEK
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $261.53 | -1.60% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $440.95 | -0.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $147.78 | -0.67% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $548.74 | -0.74% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $827.02 | -0.78% |
| argenx SEENXTBR: ARGX | $64.17B | €895.40 | +1.84% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $155.61 | -2.03% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.